BeiGene Enters $160 Million Deal for Rights to Seattle Genetics Cancer Molecule
November 05, 2019 at 09:14 AM EST
BeiGene of Beijing announced a $160 million agreement for China/Asia rights to an advanced preclinical cancer candidate from Seattle Genetics. The candidate was not described, though Seattle Genetics said it expected to start clinical trials of the molecule in the first half of 2020. Seattle Genetics is known for its antibody drug conjugate cancer drugs. BeiGene will make up to $160 million in upfront and development milestone payments, plus pay royalties on sales. More details.... Stock Symbols: (NSDQ: BGNE; HK: 06160) (NSDQ: SGEN) Share this with colleagues: // //